Covaxin third phase clinical trials results out, 77.8 per cent effective against Covid-19
Covaxin has also been found to be 65.2 percent effective against the dreaded Delta variant of Coronavirus, which is becoming the dominant strain of the virus across the world.
Share Via Email
| A+A A- By Express News Service
HYDERABAD: Covaxin, the Covid-19 vaccine developed by Hyderabad-based vaccine maker Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been found to be 77.8 percent effective in the Phase-III clinical trials.
Also, Covaxin has been found to be 93.4% effective against severe symptomatic form of Covid-19 and 63.6 percent effective against asymptomatic Covid-19.
Covaxin 77 8% effective against Covid-19: Bharat Bio - The Hindu BusinessLine thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
Bharat Biotech says that the final efficacy analysis of Covaxin shows it to be 77.8 per cent effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission. This paves the way for Covaxin to get World Health Organisation s approval for its inclusion in the Emergency Use List of Covid-19 vaccines. The company added that the analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19. The safety analysis demonstrates that adverse events reported were similar to placebo, with 12 per cent of the subjects experiencing commonly known side effects and less than 0.5 per cent of them feeling serious adverse effects. The efficacy data further demonstrates 63.6 per cent protection against asympt
Highlights
Hyderabad-based company claimed that it demonstrates overall vaccine efficacy of 77.8%.
New Delhi: The Bharat Biotech on Saturday (July 3, 2021) released the results from the Phase 3 trials of Covaxin and claimed that it demonstrates overall vaccine efficacy of 77.8%.
Over 25,798 participants were recruited between November 16, 2020, and January 7, 2021, and were randomised to Covaxin or placebo groups, of which, 24,419 received two doses of the vaccine.
In a case-driven analysis, 130 cases of symptomatic COVID-19 were reported in 16,973 (0.77%) participants with follow-up at least two weeks after the second vaccination, whereas, 24 occurred in the vaccine group and 106 in placebo recipients giving an overall vaccine efficacy of 77.8%.
Sixteen cases, one vaccinee and 15 placebo recipients met the severe symptomatic COVID-19 case definition giving a vaccine efficacy of 93.4%.
Covaxin has received emergency use authorizations in 16 countries, Bharat Biotech said.
Highlights
The vaccine offers 65.2 per cent protection against Delta variant
Phase 3 trials were conducted on 130 symptomatic Covid patients
New Delhi:
Bharat Biotech s Covaxin is overall 77.8 per cent effective against Covid, the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed.
The vaccine offers 65.2 per cent protection , it said, against the rapidly emerging Delta variant.
It was also found to be 93.4 per cent effective against severe symptomatic COVID-19, the company said.
Covaxin is a whole virus inactivated vaccine against SARS-CoV2, developed by Bharat Biotech in partnership with ICMR and NIV Pune.